Table 5 |
|||||||||
| Comparison between factors and occurrence of drug use problems, drug interactions, and other problems | |||||||||
| Factors | Drug use problems (n = 50) Frequency (Percentage, %) | Drug interactions (n = 63) Frequency (Percentage, %) | Other problems (n = 97) Frequency (Percentage, %) | ||||||
| Yes | No | p-value | Yes | No | p-value | Yes | No | p-value | |
| Elderly | |||||||||
| Yes | 17 (34.0) | 68 (45.3) | 0.215a | 37 (58.7) | 78 (56.9) | 0.933a | 57 (58.8) | 58 (56.3) | 0.836a |
| No | 33 (66.0) | 82 (54.7) | 26 (41.3) | 59 (43.1) | 40 (41.2) | 45 (43.7) | |||
| Polypharmacy | |||||||||
| Yes | 34 (68.0) | 119 (79.3) | 0.149a | 58 (92.1) | 95 (69.3) | 0.001a* | 74 (76.3) | 79 (76.7) | > 0.999a |
| No | 16 (32.0) | 31 (20.7) | 5 (7.9) | 42 (30.7) | 23 (23.7) | 24 (23.3) | |||
| Duration of hospital stay | |||||||||
| ≤ 1 week | 37 (74.0) | 106 (70.7) | 0.786a | 44 (69.8) | 99 (72.3) | 0.854a | 65 (67.0) | 78 (75.7) | 0.227a |
| > 1 week | 13 (26.0) | 44 (29.3) | 19 (30.2) | 38 (27.7) | 32 (33.0) | 25 (24.3) | |||
| Microvascular complications | |||||||||
| Yes | 31 (62.0) | 93 (62.0) | > 0.999a | 41 (65.1) | 83 (60.6) | 0.652a | 65 (67.0) | 59 (57.3) | 0.204a |
| No | 19 (38.0) | 57 (38.0) | 22 (34.9) | 54 (39.4) | 32 (33.0) | 44 (42.7) | |||
| Cardiovascular disease | |||||||||
| Yes | 27 (54.0) | 94 (62.7) | 0.358a | 53 (84.1) | 68 (49.6) | < 0.001a* | 63 (64.9) | 58 (56.3) | 0.270a |
| No | 23 (46.0) | 56 (37.3) | 10 (15.9) | 69 (50.4) | 34 (35.1) | 45 (43.7) | |||
| Renal impairment | |||||||||
| Yes | 22 (44.0) | 78 (52.0) | 0.414a | 33 (52.4) | 67 (48.9) | 0.761a | 49 (50.5) | 51 (49.5) | > 0.999a |
| No | 28 (56.0) | 72 (48.0) | 30 (47.6) | 70 (51.1) | 48 (49.5) | 52 (50.5) | |||
| Liver impairement | |||||||||
| Yes | 4 (8.0) | 7 (4.7) | 0.472b | 0 (0) | 11 (8.0) | 0.018b* | 5 (5.2) | 5 (5.8) | > 0.999a |
| No | 46 (92.0) | 143 (95.3) | 63 (100) | 126 (92.0) | 92 (94.8) | 97 (94.2) | |||
| Hyperlipidemia | |||||||||
| Yes | 17 (34.0) | 68 (45.3) | 37 (58.7) | 78 (56.9) | 57 (58.8) | 58 (56.3) | 0.836a | ||
| No | 33 (66.0) | 82 (54.7) | 0.215a | 26 (41.3) | 59 (43.1) | 0.933a | 40 (41.2) | 45 (43.7) | |
a Computed using Continuity Correction; b Computed using Fisher’s Exact Test; * Statistically significant (p < 0.05).
Zaman Huri and Fun Wee BMC Endocrine Disorders 2013 13:2 doi:10.1186/1472-6823-13-2
